Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial

Journal:

Gut

Published:

2025-08-12

DOI:

10.1136/gutjnl-2025-335456

Affiliations:

10

Authors:

16

Go to article

Institutions	Authors	Share
Peking Union Medical College Hospital (PUMCH), China	3.000000	0.19
Zhongshan Hospital, Fudan University, China	3.000000	0.19
SCG Cell Therapy - China, China	3.000000	0.19
The Sixth People's Hospital of Shenyang, China	2.000000	0.13
SCG Cell Therapy Pte Ltd (SCG), Singapore	2.000000	0.13
SCG Cell Therapy - Germany, Germany	1.000000	0.06
The First Hospital of China Medical University, China	1.000000	0.06
Technical University of Munich (TUM), Germany	0.333333	0.02
Helmholtz Zentrum München - German Research Center for Environmental Health (HMGU), Germany	0.333333	0.02
German Center for Infection Research (DZIF), Germany	0.333333	0.02

Interested in Oncology and Carcinogenesis?